Some Researchers Are Calling Alzheimer's 'Type 3 Diabetes' — Here's the Evidence

Alzheimer's disease and type 2 diabetes are usually discussed as entirely separate conditions — one a metabolic disease, one a neurodegenerative disease. But researchers studying both have noticed a consistent pattern: people with type 2 diabetes have roughly double the risk of developing Alzheimer's compared to people without it. And the connection is not simply that both conditions share risk factors like age or inflammation. There is a more specific biological link — one involving insulin signaling directly in the brain — that some researchers believe is central to Alzheimer's pathology. They've given it a name: type 3 diabetes.

The 'type 3 diabetes' framing was introduced in a 2005 paper by Suzanne de la Monte and Jack Wands at Brown University, and remains controversial — it is not an official clinical diagnosis, and many Alzheimer's researchers dispute both the terminology and the degree to which insulin resistance is a causal driver versus a correlate of the disease. What is less disputed is the underlying biology: the brain is an insulin-sensitive organ, insulin signaling in the brain plays important roles in neuronal survival, synaptic plasticity, and cognition, and brain insulin resistance — reduced responsiveness of brain cells to insulin — is documented in Alzheimer's disease tissue and correlates with cognitive decline. The brain's ability to clear amyloid also depends on the [glymphatic waste clearance system](/blog/your-brain-washes-itself-during-sleep) that only operates during deep sleep.

Insulin receptors are expressed throughout the brain, with particularly high density in the hippocampus, cortex, and hypothalamus — regions central to memory, cognition, and metabolic regulation. Brain insulin signaling promotes neuronal survival, regulates the processing of amyloid precursor protein (the precursor to the amyloid-beta plaques characteristic of Alzheimer's), and modulates tau phosphorylation — the process by which tau protein becomes hyperphosphorylated and forms neurofibrillary tangles, the second defining pathological feature of Alzheimer's. When insulin signaling in the brain is impaired, both amyloid processing and tau phosphorylation are disrupted in directions that promote Alzheimer's pathology.

The Epidemiological Evidence

The epidemiological association between type 2 diabetes and Alzheimer's disease is well-established across multiple large prospective studies. A meta-analysis of prospective cohort studies found that people with type 2 diabetes have approximately 56% higher risk of developing Alzheimer's disease and approximately 127% higher risk of any dementia compared to people without diabetes, after adjustment for known confounders. This association holds across different populations and is not fully explained by shared vascular risk factors, suggesting a metabolic-neurological mechanism beyond simply shared correlates.

Hyperinsulinemia — chronically elevated blood insulin, characteristic of insulin resistance before glucose control fails — has been independently associated with Alzheimer's risk in some studies. This metabolic dysfunction often co-occurs with [leptin resistance](/blog/leptin-resistance-why-your-hunger-signals-break), creating a compounding cycle of broken hunger and metabolic signals. Midlife obesity — often driven by [ultra-processed food](/blog/how-ultra-processed-food-overrides-your-biology) that overrides satiety signaling — is a strong driver of insulin resistance and is associated with elevated dementia risk decades later in longitudinal data. And insulin-sensitizing interventions — both lifestyle-based and pharmacological — are being actively investigated as potential Alzheimer's prevention or treatment strategies, with some early results suggesting benefit in specific subgroups.

The Mechanism: How Insulin Resistance May Drive Alzheimer's Pathology

The molecular connections between insulin resistance and Alzheimer's pathology are specific and multiple. First, insulin normally promotes the non-amyloidogenic processing of amyloid precursor protein — the pathway that does not produce the amyloid-beta fragments that aggregate into plaques. Impaired insulin signaling shifts processing toward the amyloidogenic pathway, increasing amyloid-beta production. Second, insulin signaling normally inhibits GSK-3β, a kinase that phosphorylates tau. When insulin signaling is impaired, GSK-3β becomes overactive, increasing tau hyperphosphorylation and neurofibrillary tangle formation.

Third, insulin-degrading enzyme (IDE) — which degrades both insulin and amyloid-beta — is competed for between its two substrates. In states of hyperinsulinemia, elevated insulin may competitively reduce IDE's capacity to clear amyloid-beta, allowing it to accumulate. This specific mechanism — where the chronically elevated insulin of insulin resistance impairs the brain's amyloid clearance — is one of the more direct proposed links between metabolic dysfunction and Alzheimer's pathology, though its relative contribution in humans is still being investigated.

What the Evidence Doesn't Establish

The 'type 3 diabetes' terminology is not universally accepted, and for good reason: it implies a degree of certainty about causality that the evidence does not yet fully support. Alzheimer's disease is multifactorial — genetics (particularly APOE4 genotype), age, vascular health, inflammation, and other factors all contribute, and the relative weight of brain insulin resistance as a causal driver versus an associated feature remains an active area of research. Clinical trials testing insulin sensitizers as Alzheimer's treatments have produced mixed results — some benefit in subgroups, no consistent benefit across all patients.

What the evidence does support with reasonable confidence is: there is a specific, mechanistically plausible biological relationship between insulin signaling and Alzheimer's pathology; people with type 2 diabetes have meaningfully elevated Alzheimer's risk that is not fully explained by shared risk factors; and the [epigenetic changes](/blog/your-lifestyle-changes-your-gene-expression) driven by metabolic dysfunction may compound the damage at the gene expression level; and the metabolic drivers of insulin resistance — poor diet, physical inactivity, sleep disruption, [chronic stress](/blog/chronic-stress-shrinks-your-brain) — are modifiable in ways that reduce both metabolic and potentially neurological risk. Understanding [why traditional diets fail](/blog/why-diets-fail-metabolic-adaptation) is important context for addressing these drivers sustainably.

What You Can't Unsee

The brain is not metabolically isolated. It is an insulin-sensitive organ with insulin receptors throughout, performing insulin-dependent functions that include the regulation of the very proteins — amyloid-beta and tau — that define Alzheimer's disease. The epidemic of insulin resistance that manifests as type 2 diabetes in the body may be manifesting as something analogous in the brain — with consequences that take decades to become clinically apparent but that begin at the molecular level much earlier. Whether or not 'type 3 diabetes' becomes accepted nomenclature, the underlying biology is real, the risk association is documented, and the modifiable drivers are the same ones that affect metabolic health everywhere else in the body.